A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer

Programmed cell death 1 ligand (PD-L1) blockade has been used therapeutically in the treatment of ovarian cancer, and potential combination treatment approaches are under investigation to improve the treatment response rate. The increased dependence on glutamine is widely observed in various type of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing-Jing, Siu, Michelle Kwan-Yee, Jiang, Yu-Xin, Leung, Thomas Ho-Yin, Chan, David Wai, Wang, Huo-Gang, Ngan, Hextan Yuen-Sheung, Chan, Karen Kar-Loen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698585/
https://www.ncbi.nlm.nih.gov/pubmed/34944392
http://dx.doi.org/10.3390/biom11121749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698585/
https://www.ncbi.nlm.nih.gov/pubmed/34944392
http://dx.doi.org/10.3390/biom11121749

Ejemplares similares